Medical system firm IDEXX Laboratories, Inc. (NASDAQ: IDXX) on Monday reported larger revenues and web earnings for the fourth quarter of 2024.
- Fourth-quarter revenues elevated 6% yearly to $954.3 million; natural income development was 6%
- Web earnings attributable to shareholders moved as much as $216.1 million in This autumn from $194.5 million a yr earlier
- On a per-share foundation, fourth-quarter earnings rose to $2.62 from $2.32 in This autumn 2023
- For fiscal 2025, the administration expects revenues to be within the vary of $4.06 billion to $4.17 billion, reflecting a development of 4-7%
- Full-year natural income development is anticipated to be between 6% and 9%
- The administration is searching for earnings of $11.74 per share to $12.24 per share for FY25, a rise of 10-15% on a reported foundation
